<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180205038617N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-04-09</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Effect  of prednisolon acetete drop on pupil dilation and ocular pain after cataract surgery</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation the effect of topical prednisolon acetate 1% on the pupillary diameter and ocular pain after uncomplicated cataract surgery in diabetic and non diabetic patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2017-03-13</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/29548</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: If non-diabetic patients have inclusion criteria, they will be divided in to 2 groups of A and B through simple random sampling and using envelopes. Also, diabetic patients that have inclusion criteria will be divided in to 2 groups of C and D through simple random sampling and using envelopes, Blinding description: Patients in control group were given placebo which its appearance was the same as the medication which was administered for intervention group. All participants, researcher, surgeons and outcome investigator were blind about the medication were used for each patient.</study_design>
      <phase>3</phase>
      <hc_freetext>Effect of topical dipped prednisolone acetate 1% on pupil dilatation and pain after uncomplicated cataract surgery.</hc_freetext>
      <i_freetext>Intervention 1: Intervention 1: Non-diabetic patients who recieve topical prednisone acetate 1%  drop, every six hours, 24 hours before surgery. Patients are advised to shake the bottle before using. The administered drop is produced by Sinadaroo company. Intervention 2: Intervention group: Diabetic patients who receive topical prednisone acetate 1%  every six hours, 24 hours before surgery. Patients are advised to shake the bottle before using. The administered drop is produced by Sinadaroo company. Intervention 3: Control group1: Non-Diabetic patients who receive preservative- free artificial tears every six hours, 24 hours before surgery. The administered drop is produced by Sinadaroo company. Intervention 4: Control group2: Diabetic patients who receive preservative- free artificial tears every six hours, 24 hours before surgery. The administered drop is produced by Sinadaroo company.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Total data of patients and research result are shareable after undetectabling of patient since 2019

When:
From2019

To whom:
Researchers of academic center only

Conditions:
Clinical and practical usage is okay

Where to obtain:
Email:Hoseinzadea1@mums.ac.ir  Tel:00989122276382

How to obtain:
Send an email to Hoseinzadeha1@mums.ac.ir

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hoseinzadeh Abolfazl</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No23,Besat ave.,Ahmadabad Blvd.</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9175934333</zip>
        <telephone>+98 51 3840 2924</telephone>
        <email>Hoseinzadeha1@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hoseinzadeh abolfazl</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No23,Beesat Blvd,Ahmadabad Town</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9175934333</zip>
        <telephone>+98 51 3840 2924</telephone>
        <email>Hoseinzadeha1@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>In non- diabetic group: Patients over 40 years old with cortical cataract, posterior subcapsular or grade 2 to 3 nuclear sclerosis  that have indication  of phacoemulsification surgery  with general anesthesia
In diabetic group: Patients over 40 years old with cortical cataract, posterior subcapsular or grade 2 to 3 nuclear sclerosis  that have pseudoexfuliation or non proliferative diabetic retinopathy and have indication  of phacoemulsification surgery  with general anesthesia</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of previous intraocular surgery
collagen vascular disease
history of previous or current topical steroids, alphablocker or antiglaucoma medication
history of previous or current systemic steroid use
history of uveitis
mature cataract</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>H25.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Age-related incipient cataract</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Placebo</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention 1: Non-diabetic patients who recieve topical prednisone acetate 1%  drop, every six hours, 24 hours before surgery. Patients are advised to shake the bottle before using. The administered drop is produced by Sinadaroo company.</i_keyword>
      <i_keyword>Intervention group: Diabetic patients who receive topical prednisone acetate 1%  every six hours, 24 hours before surgery. Patients are advised to shake the bottle before using. The administered drop is produced by Sinadaroo company.</i_keyword>
      <i_keyword>Control group1: Non-Diabetic patients who receive preservative- free artificial tears every six hours, 24 hours before surgery. The administered drop is produced by Sinadaroo company.</i_keyword>
      <i_keyword>Control group2: Diabetic patients who receive preservative- free artificial tears every six hours, 24 hours before surgery. The administered drop is produced by Sinadaroo company.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Horizontal pupilary diameter. Timepoint: The diameter of the pupilary horizontal diameter is measured at the beginning and at the end of the operation using caliber and is divided into two groups up and down six millimeters. Method of measurement: Caliber.</prim_outcome>
      <prim_outcome>The score of post-operative pain which is measured by Visual Analog Scale for pain questionnaire. Timepoint: 24 hours after surgery. Method of measurement: Score of Visual Analog Scale for pain questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Post operative photophobia. Timepoint: 24 hours after surgery. Method of measurement: Visual Analogue Scale for pain questionnaire.</sec_outcome>
      <sec_outcome>Foreign body sensation. Timepoint: 24 hours after surgery. Method of measurement: Visual Analogue Scale for pain questionnaire.</sec_outcome>
      <sec_outcome>Itching. Timepoint: 24 hours after surgery. Method of measurement: Visual Analogue Scale for pain questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-01-28</approval_date>
        <contact_name>Ethics committee of Mashhad University of Medical Sciences</contact_name>
        <contact_address>Khatamolanbia Hospital, Gharani street Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
